The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Open accessAbstract
BACKGROUND: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event. METHODS: We randomly assigned patients with type 2 diabetes who had had a myocardial infarction or who had been hospitalized for unstable angina within the previous 180 days to receive lixisenatide or placebo in addition to locally determined standards of care. The trial was designed with adequate statistical power to assess whether lixisenatide was noninferior as well as superior to placebo, as defined by an upper boundary of the 95% confidence interval for the hazard ratio of less than 1.3 and 1.0, respectively, for the primary composite end point of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: The 6068 patients who underwent randomization were followed for a median of 25 months. A primary end-point event occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (hazard ratio, 1.02; 95% confidence interval [CI], 0.89 to 1.17), which showed the noninferiority of lixisenatide to placebo (P<0.001) but did not show superiority (P=0.81). There were no significant between-group differences in the rate of hospitalization for heart failure (hazard ratio in the lixisenatide group, 0.96; 95% CI, 0.75 to 1.23) or the rate of death (hazard ratio, 0.94; 95% CI, 0.78 to 1.13). Lixisenatide was not associated with a higher rate of serious adverse events or severe hypoglycemia, pancreatitis, pancreatic neoplasms, or allergic reactions than was placebo. CONCLUSIONS: In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events. (Funded by Sanofi; ELIXA ClinicalTrials.gov number, NCT01147250.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“in the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial,14 the GLP-1–receptor agonist lixisenatide, which is shorter-acting than and structurally dissimilar to liraglutide, did not show any cardiovascular benefit in patients with diabetes and a recent acute coronary syndrome.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“No increased risk of heart failure hospitalization has been identified in the cardiovascular outcomes trials of the GLP-1 RAs lixisenatide, liraglutide, semaglutide, exenatide once weekly, albiglutide, or dulaglutide compared with placebo (261,264,265,296,297).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [297]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [641]
Experimental — accuracy not yet measuredIn the citing paper
“The study showed that lixisenatide is not inferior, although not superior, to placebo in cardiovascular safety.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [55]
In the citing paper
“The indication is to effectively reduce glycosylated hemoglobin levels in patients with T2DM by reducing fasting and postprandial blood glucose levels (61, 62).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [61]
In the citing paper
“In the ELIXA trial, lixisenatide 10 or 20 μg o.d. was non-inferior to placebo, but did not significantly affect a four-point MACE (three-point MACE plus hospitalization for unstable angina) in patients with T2DM post-ACS.158”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“Most GLP-1 RAs had a neutral effect on risk of HF hospitalization in the placebo-controlled RCTs assessing CV safety of glucose-lowering medications in patients with T2DM with or at high risk of ASCVD, despite increasing heart rate by 3-5 b.p.m. 70,72,158- 163,544”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER, dulaglutide, efpeglenatide) have a neutral effect on the risk of HF hospitalization, and should be considered for glucose-lowering treatment in patients with T2DM at risk of or with HF. 70,158-164,545 IIa A”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) was the first to report and showed that the short-acting GLP-1 receptor agonist lixisenatide had no impact on MACEs in 6068 patients after an acute coronary syndrome.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [224]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“No increased risk of heart failure hospitalization has been identi fi ed in the cardiovascular outcomes trials of the GLP-1 receptor agonists lixisenatide, liraglutide, semaglutide, exenatide once-weekly, albiglutide, or dulaglutide compared with placebo ( Table 10.3 B ) (203,204,207 -209).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“However, two GLP-1 analogues tested in two studies demonstrated no advantage in influencing cardiovascular outcome.278,279”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [279]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [23]
In the citing paper
“In these trials, GLP-1 receptor agonists had a neutral effect on the risk for HF hospitalization.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,016
Žerovnik, Š., Kos, M., & Locatelli, I. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-051549 · Cited by 27
Zhang, X., Wang, M., Wang, X., Zhu, Z., Zhang, W., Zhou, Z., Tang, W., & Li, Q. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.12.007 · Cited by 26
Management of diabetic kidney disease: where do we stand?: A narrative review
Sindhu, D., Sharma, G. S., & Kumbala, D. R. (2023) · Medicine · doi:10.1097/md.0000000000033366 · Cited by 27
Villaschi, A., Ferrante, G., Cannata, F., Pini, D., Pagnesi, M., Corrada, E., Reimers, B., Mehran, R., Federici, M., Savarese, G., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02362-6 · Cited by 26
Kalra, S. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0197-4 · Cited by 28
Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome
Chatterjee, S., Ghosal, S., & Chatterjee, S. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i18.441 · Cited by 28
Nyström, T., Santos‐Pardo, I., Hedberg, F., Wardell, J., Witt, N., Cao, Y., Bojö, L., Nilsson, B., & JENDLE, J. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00325 · Cited by 25
Cardiovascular Risks and Benefits of Medications Used for Weight Loss
Bramante, C. T., Raatz, S. J., Bomberg, E. M., Bensignor, M. O., & Ryder, J. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00883 · Cited by 27
Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes
Libianto, R., Davis, T. M. E., & Ekinci, E. I. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50472 · Cited by 26
Shin, S., Claggett, B. L., Pfeffer, M. A., Skali, H., Liu, J., Aguilar, D. A., Díaz, R., Dickstein, K., Gerstein, H. C., Køber, L., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1790 · Cited by 25
Self-citationClemson University, C. E. S. (2006) · Oxford University Press eBooks · doi:10.1093/med/9780199543724.001.0001 · Cited by 28
Acid-base and electrolyte disorders associated with the use of antidiabetic drugs
Filippatos, T. D., Tzavella, E., Rizos, C. V., Elisaf, M., & Liamis, G. L. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361400 · Cited by 27
Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease
Aguilar, D. A. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003316 · Cited by 25
A New Chapter for Diabetic Kidney Disease
de Boer, I. H. (2017) · New England Journal of Medicine · doi:10.1056/nejme1708949 · Cited by 26
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Tobaiqy, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00629-x · Cited by 25
Treatment and practical considerations of diabetic kidney disease
Bilen, Y., Almoushref, A., Alkwatli, K., Osman, O., Mehdi, A., & Sawaf, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1264497 · Cited by 28
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 27
Khadke, S., Kumar, A., Bhatti, A. W., Dani, S. S., Al-Kindi, S. G., Nasir, K., Virani, S. S., Upadhyay, J., Garcia-Banigan, D. C., Abraham, S., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.10.448 · Cited by 27
Gargiulo, P., Savarese, G., D’Amore, C., Martino, F. D., Lund, L. H., Marsico, F., Dellegrottaglie, S., Marciano, C., Trimarco, B., & Filardi, P. P. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.09.006 · Cited by 25
Li, X., Jia, F., Zhu, Z., & Huang, L. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1593996 · Cited by 25
Ericsson, Å., & Fridhammar, A. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1614009 · Cited by 25
Management of type 2 diabetes: consensus of diabetes organizations
Quattrocchi, E. J., Goldberg, T., & Marzella, N. (2020) · Drugs in Context · doi:10.7573/dic.212607 · Cited by 33
Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials
Ludwig, L., Darmon, P., & Guerci, B. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01034-3 · Cited by 25
Gómez‐Huelgas, R., Sanz‐Cánovas, J., Cobos-Palacios, L., Sampalo, A. L., & Perez-Belmonte, L. M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.11.008 · Cited by 26
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N. M., Lalic, K. S., Škrha, J., Valensi, P. E., & Ceriello, A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0667-2 · Cited by 25
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258401 · Cited by 27
Effects of liraglutide on hemodynamic parameters in patients with heart failure
Zhang, J. Y., Wang, X. Y., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18570 · Cited by 26
Wägner, A. M., Miranda-Calderín, G., Ugarte-Lopetegui, M. A., Marrero-Santiago, H., Suárez-Castellano, L., López-Madrazo, M. J., Alberiche-Ruano, M. P., Ahmed, N. A., Alemán, C., Castellot-Martín, A., et al. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.010 · Cited by 25
The use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential
Mustafa, O. G., & Whyte, M. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3191 · Cited by 27
Uneda, K., Kawai, Y., Yamada, T., Kinguchi, S., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-89620-7 · Cited by 27
The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure
Scirica, B. M. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0184 · Cited by 25
Hunt, B., Kragh, N., McConnachie, C. C., Valentine, W. J., Rossi, M. C., & Montagnoli, R. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.354 · Cited by 24
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Tang, A. S. P., Hsu, J. T. Y., Chong, S. K. S., Quek, J., Shek, G., Sulaimi, F., Chan, K. E., Anand, V. V., Chong, B., Mehta, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02840-3 · Cited by 27
Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
Diabetes and Hypertension: Clinical Update
Khangura, D., Kurukulasuriya, L. R., Whaley‐Connell, A. T., & Sowers, J. R. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy025 · Cited by 25
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease
Jiménez, D. L., Cherney, D. Z. I., Bjornstad, P., Castilla‐Guerra, L., & Miramontes‐González, J. P. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00384.2017 · Cited by 26
Cardioprotective diabetes drugs: what cardiologists need to know
Brown, J. M., & Everett, B. M. (2019) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000181 · Cited by 23
Singh, A. K., & Singh, R. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.051 · Cited by 24
Advances in the management of diabetes: therapies for type 2 diabetes
Tsoutsouki, J., Wunna, W., Chowdhury, A., & Chowdhury, T. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137404 · Cited by 24
ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
Liew, A., Bavanandan, S., Prasad, N., Wong, M. G., Chang, J. M., Eiam‐Ong, S., Hao, C., Lim, C. Y., Lim, S. K., Oh, K., et al. (2020) · Nephrology · doi:10.1111/nep.13785 · Cited by 24
Banach, M., Gaiță, D. I., Haluzı́k, M., Janež, A., Kamenov, Z. A., Kempler, P., Lalic, N. M., Linhart, A., Mikhailidis, D. P., Nocoń, A., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108535 · Cited by 24
GLP‐1 RA and atrial fibrillation in the cardiovascular outcome trials
Hamedi, Z., Mishriky, B. M., Okunrintemi, V., Powell, J. R., & Cummings, D. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3436 · Cited by 23
Duan, X.-Y., Liu, S.-Y., & Yin, D. (2021) · Medicine · doi:10.1097/md.0000000000026431 · Cited by 24
Diabetes, Vascular Aging and Stroke: Old Dogs, New Tricks?
Penlioglou, T., Stoian, A. P., & Παπάνας, Ν. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194620 · Cited by 27
Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
Albert, S. G., Wood, E. M., & Ahir, V. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102696 · Cited by 25
Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
Al‐Sadawi, M., Aslam, F. M., Tao, M., Alsaiqali, M., Almasry, I. O., Fan, R., Rashba, E. J., & Singh, A. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101218 · Cited by 26
Brønden, A., Christensen, M., Glintborg, D., Snorgaard, O., Kofoed‐Enevoldsen, A., Madsen, G. K., Toft, K., Kristensen, J. K., Højlund, K., Hansen, T. K., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.15157 · Cited by 27
Hinnen, D., & Strong, J. L. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0014 · Cited by 24
Huang, C., Wang, W., Sung, S., Chen, C., Lip, G. Y. H., Cheng, H., & Chiang, C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13342 · Cited by 24
Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus
Ikeda, M., & Shimazawa, R. (2019) · Journal of General and Family Medicine · doi:10.1002/jgf2.244 · Cited by 24
Doğruel, H., & Balcı, M. K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.446 · Cited by 27
Goldenberg, R. M., Ahooja, V., Clemens, K. K., Gilbert, J. D., Poddar, M., & Verma, S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.005 · Cited by 23
Lecis, D., Prandi, F. R., Barone, L., Belli, M., Sergi, D., Longo, S., Muscoli, S., Romeo, F., Federici, M., Lerakis, S., et al. (2023) · Biomolecules · doi:10.3390/biom13121695 · Cited by 23
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
MacIsaac, R. J., Trevella, P., & Ekinci, E. I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13609 · Cited by 27
Liu, Y., He, L., Han, S., Ping, F., Li, W., Xu, L., Zhang, H., & Li, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039446 · Cited by 25
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 25
Pharmacological management of type 2 diabetes: what’s new in 2017?
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1376652 · Cited by 23
The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
García-Carro, C., Vergara, A., Agraz, I., Jacobs-Cachá, C., Espinel, E., Serón, D., & Soler, M. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060864 · Cited by 25
Diabetes and Vascular Disease: Is It All About Glycemia?
Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 23
Giorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14055 · Cited by 23
Davies, M. J., Bianchi, C., & Prato, S. D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 24
Giorgino, F., Caruso, I., & Napoli, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108478 · Cited by 24
Rai, A. K., Lee, B., Gomez, R., Rajendran, D., Khan, M., & Garikipati, V. N. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.612722 · Cited by 23
Wei, J., Yang, C., Leng, W., Ding, L., & Zhao, G. (2021) · The Clinical Respiratory Journal · doi:10.1111/crj.13372 · Cited by 23
Ertuğlu, L. A., Porrini, E., Hornum, M., Demiray, A., Afşar, B., Ortíz, A., Covic, A. C., Rossing, P. R., & Kanbay, M. (2021) · Transplant International · doi:10.1111/tri.13883 · Cited by 25
Recent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 23
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 23
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 26
Trombara, F., Cosentino, N., Bonomi, A., Ludergnani, M., Poggio, P., Gionti, L., Baviera, M., Colacioppo, P., Roncaglioni, M. C., Leoni, O., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01758-y · Cited by 24
Jung, H., Tittel, S. R., Schloot, N. C., Heitmann, E., Otto, T., Lebrec, J., Pavel, M., & Lanzinger, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15038 · Cited by 23
Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pieters-van den Bos, I. C., Vendrik, K. E. W., Hoekstra, T., Bruno, M. J., Diamant, M., van Raalte, D. H., et al. (2017) · Diabetes Care · doi:10.2337/dc16-0836 · Cited by 23
Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies
Tarquini, R., Pala, L., Brancati, S., Vannini, G., Cosmo, S. D., Mazzoccoli, G., & Rotella, C. M. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170705111356 · Cited by 23
The Genetic Link Between Diabetes and Atherosclerosis
Ross, S. A., Gerstein, H. C., & Paré, G. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.01.016 · Cited by 23
Self-citationYin, T., Bi, Y., Li, P., Shen, S., Xiong, X.-L., Gao, L., Jiang, C., Wang, Y., Feng, W., & Zhu, D. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0412-6 · Cited by 23
Zhang, X., Shao, F., Zhu, L., Ze, Y., Zhu, D., & Bi, Y. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0246-x · Cited by 26
Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine
Valencia, W. M., Botros, D., Vera-Nunez, M. A., & Dang, S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1052-y · Cited by 26
Muskiet, M. H. A., Bunck, M. C. M., Heine, R. J., Cornér, A., Yki‐Järvinen, H., Eliasson, B., Joles, J. A., Diamant, M., Tonneijck, L., & van Raalte, D. H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.001 · Cited by 23
Chudleigh, R. A., Platts, J. K., & Bain, S. C. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s193693 · Cited by 23
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 25
Zhao, H., Liu, Y., Liu, M., Xu, Y., Ling, Q., Lin, W., Zhang, J., Yan, Z., Ma, J., Li, W., et al. (2023) · Drugs · doi:10.1007/s40265-023-01932-2 · Cited by 24
Diabetes Mellitus in Acute Coronary Syndrome
Stampouloglou, P. K., Anastasiou, A., Bletsa, E., Lygkoni, S., Chouzouri, F., Xenou, M., Κατσαρού, Ο., Theofilis, P., Zisimos, K., Tousoulis, D., et al. (2023) · Life · doi:10.3390/life13112226 · Cited by 30
Gaggini, M., Sabatino, L., Suman, A. F., Chatzianagnostou, K., & Vassalle, C. (2025) · Cells · doi:10.3390/cells14050387 · Cited by 29
Cardiovascular effects of anti-diabetes drugs
Younk, L. M., Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1195368 · Cited by 23
Chen, H., Zhou, X., Chen, T., Liu, B., Jin, W., Gu, H., Hong, T., & Zhang, G. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0198-3 · Cited by 23
Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective
Thompson, P. L., & Davis, T. M. E. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.10.008 · Cited by 23
Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip
Luconi, M., Cantini, G., Ceriello, A., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.126 · Cited by 24
Chiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes
Martins, E. B., Lima, E. G., Pitta, F. G., Carvalho, L. N. S., de Queiroz, T. D., & Junior, C. V. S. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.9.1283 · Cited by 23
Caparrotta, T. M., Templeton, J. B., Clay, T. A., Wild, S. H., Reynolds, R. M., Webb, D. J., & Colhoun, H. M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01021-1 · Cited by 24
Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article
Mgbemena, O. N., Zhang, Y., & Velarde, G. (2021) · Cureus · doi:10.7759/cureus.19398 · Cited by 23
Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01773-z · Cited by 25
Ali, M. U., Mancini, G. B. J., Fitzpatrick‐Lewis, D., Connelly, K. A., O’Meara, E., Zieroth, S. R., & Sherifali, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02154-w · Cited by 23
Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Trevella, P., Ekinci, E. I., & MacIsaac, R. J. (2024) · Nephrology · doi:10.1111/nep.14336 · Cited by 22
Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.
Kankanala, S., Syed, R. M., Gong, Q., Ren, B., Rao, X., & Zhong, J. (2016) · PubMed Central · Cited by 22
Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back
Mosenzon, O., Pollack, R. M., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dcs15-3003 · Cited by 24
Rahelić, D., Javor, E., Lucijanić, T., & Skelin, M. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1226514 · Cited by 23
Pechenov, S., Bhattacharjee, H., Yin, D., Mittal, S., & Subramony, J. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.01.006 · Cited by 22
Metadata
- Authors
- Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., Probstfield, J. L., Riddle, M. C., Solomon, S. D., & Tardif, J.-C.
- Affiliations
- Brigham and Women's Hospital (US)
- Stavanger University Hospital (NO)
- McMaster University (CA)
- Copenhagen University Hospital (DK)
- Sanofi (United States) (US)
- University of Zurich (CH)
- University of Washington Medical Center (US)
- Oregon Health & Science University (US)
- Montreal Heart Institute (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-03
- Volume
- 373
- Issue
- 23
- Pages
- 2247-2257
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2282578582
- Cited by
- 2,409
- References
- 38
- Citations by year
- 2026: 136 · 2025: 175 · 2024: 182 · 2023: 165 · 2022: 191 · 2021: 250 · 2020: 281 · 2019: 251 · 2018: 290 · 2017: 278 · 2016: 202 · 2015: 4
- FWCI
- 224.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- lixisenatide, type 2 diabetes, acute coronary syndrome, myocardial infarction, unstable angina, GLP-1 receptor agonists, cardiovascular outcomes, non-inferiority, major adverse cardiovascular events, heart failure hospitalization, serious adverse events, hypoglycemia, pancreatitis, pancreatic neoplasms, allergic reactions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Peptides, Proportional Hazards Models, Treatment Failure, Kaplan-Meier Estimate, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
